29A:FRA
Amphastar Pharmaceuticals, Inc
€18.17
arrow_upward
+1.34%(+0.24) 1 日
5月4日, 22:00:00 GMT+2 · EUR
search
すべての記号
1 日
5 日
1 か月
6 か月
年初来
1 年
5 年
最大
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_auto29A の上位の分析情報を生成しています...
始値
€18.17
高値
€18.17
安値
€18.17
時価総額
10.13億
平均出来高
0.00
取引量
0.00
52 週高値
€25.96
52 週安値
€15.26
従業員数
1976
ニュース記事
ウェブの情報から
プロフィール
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
Amphastar Pharmaceuticals, Inc について